In 2021, a research team led by Prof. Heiko Lickert from Helmholtz Munich discovered the insulin-inhibitory receptor "Inceptor" and its role as a suppressor of the insulin signaling pathway. Now, the ...

In 2021, a research team led by Prof. Heiko Lickert from Helmholtz Munich discovered the insulin-inhibitory receptor "Inceptor" and its role as a suppressor of the insulin signaling pathway.

In 2021, a research team discovered the insulin-inhibitory receptor 'Inceptor' and its role as a suppressor of the insulin signaling pathway. Now, the researchers have unlocked another ...

Three years ago, the inceptor protein was discovered and its role as an inhibitor of the insulin signaling pathway was described. Inceptor and the insulin receptor are located on the surface of ...

Together with his team, they discovered Inceptor in 2021 and described its role as an inhibitor of the insulin signaling pathway. Both Inceptor and the insulin receptor are located on the surface ...

Protagonist Therapeutics Inc. has selected PN-881, an oral peptide interleukin-17 (IL-17) antagonist, as a development candidate for the treatment of immune-mediated skin diseases.

Startup company Pep2tango Therapeutics Inc., unveiled with backing by Versant Ventures, is advancing unimolecular multireceptor peptide agonists that target GLP-1, GIP, amylin and calcitonin receptors ...